Physician

Melissa Leigh Larson, M.D.

According to 2025 Medicare claims, Melissa Larson, M.D. (NPI: 1912967688) practices hematology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is RUSH UNIVERSITY MEDICAL GROUP (NPI: 1093819542; TIN: 91-1780160) and primary practice location at 60607-3106. Larson is affiliated with the Franciscan ACO, Inc. (ACO ID: A2550) and CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under both the MSSP and REACH models.

Larson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 339 traditional Medicare patients, billed 762 HCPCS/CPT codes, and received $70,314 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,192 prescription claims across 201 beneficiaries totaling $7,566,524 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 54 claims. Open Payments data shows 3 records totaling $14,968. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $616,965 to $7,566,524. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	242	824	$69,017
2016	330	924	$83,971
2017	313	1,117	$106,520
2018	323	1,073	$112,614
2019	262	862	$91,727
2020	255	694	$65,421
2021	282	711	$74,530
2022	324	773	$73,034
2023	405	822	$82,056
2024	339	762	$70,314

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	49	354	$616,965
2016	54	475	$1,219,219
2017	77	484	$1,323,240
2018	85	642	$1,719,519
2019	77	479	$1,514,243
2020	81	567	$1,678,658
2021	90	558	$2,107,355
2022	130	657	$2,191,936
2023	216	1,256	$7,640,250
2024	201	1,192	$7,566,524

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	54	$328,199
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	41	41	$142
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	167	336	$110
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	50	129	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	103	115	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	63	75	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	155	4,333	$3,096,036
Sprycel	Dasatinib	45	1,350	$767,025
Imbruvica	Ibrutinib	33	926	$530,189
Lenalidomide	Lenalidomide	32	896	$512,071
Venclexta	Venetoclax	53	1,294	$406,996

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$78	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$14,890	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Melissa Leigh Larson, M.D.?

Tedicare shows public-source Medicare data for Melissa Leigh Larson, M.D. (NPI 1912967688), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Melissa Leigh Larson, M.D. have ACO affiliation data?

Melissa Leigh Larson, M.D. is shown with ACO affiliation data for Franciscan ACO, Inc. (MSSP, ACO ID A2550) and CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Melissa Leigh Larson, M.D.?

Melissa Leigh Larson, M.D. is linked to RUSH UNIVERSITY MEDICAL GROUP (billing NPI 1093819542) in the available physician profile data.

Does Melissa Leigh Larson, M.D. have Open Payments data?

Melissa Leigh Larson, M.D. has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.